Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma is a research paper published in Annals of Clinical and Translational Neurology (2020). On theSindex it has a DataRank of 0.578. It has been cited 46 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.578
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH/NCI Cancer Center Support Grant
Grant: P30CA008748
NCI-Cancer Therapy Evaluation Program
Grant: NIH/NCI U01CA069856
NCATS NIH HHS
Grant: UL1 TR001863
NINDS NIH HHS
Grant: R35 NS105109
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5U01CA069856-06
PHASE I STUDIES OF ANTICANCER AGENTS
FWCI
2.24
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals